BioRestorative Therapies (BRTX) Change in Accured Expenses (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Change in Accured Expenses came in at $332296.0 in Q4 2025, up 433.83% YoY from $62248.0 in Q4 2024, and up 162.59% on a QoQ basis from $126545.0 in Q3 2025.
BioRestorative Therapies (BRTX) Change in Accured Expenses (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Change in Accured Expenses data on file, last reported at $332296.0 in Q4 2025.
- Quarterly Change in Accured Expenses rose 433.83% year-over-year to $332296.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $195281.0 (up 495.39% YoY) and the FY2025 annual result came in at $195281.0, up 495.39% from the prior year.
- Change in Accured Expenses rose to $332296.0 in Q4 2025, from $126545.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $332296.0 in Q4 2025 to a low of -$466875.0 in Q1 2025.
- A 5-year average of $80873.6 and a median of $145932.5 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 1626390.0% — and 2024, when it slumped 491.19%.
- Tracing BRTX's Change in Accured Expenses over 5 years: stood at $284658.0 in 2021, then slumped by 94.58% to $15423.0 in 2022, then soared by 955.14% to $162734.0 in 2023, then sank by 61.75% to $62248.0 in 2024, then surged by 433.83% to $332296.0 in 2025.
- The last three Change in Accured Expenses figures came in at $332296.0 (Q4 2025), $126545.0 (Q3 2025), and $203315.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | 332,296.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 332,296.00 |
| Dec 31, 2025 | 332,296.00 |
| Sep 30, 2025 | 126,545.00 |
| Sep 30, 2025 | 126,545.00 |
| Jun 30, 2025 | 203,315.00 |
| Jun 30, 2025 | 203,315.00 |
| Mar 31, 2025 | -466,875.00 |
| Mar 31, 2025 | -466,875.00 |
| Dec 31, 2024 | 62,248.00 |
| Dec 31, 2024 | 62,248.00 |
| Sep 30, 2024 | 234,615.00 |
| Sep 30, 2024 | 234,615.00 |
| Jun 30, 2024 | 138,525.00 |
| Jun 30, 2024 | 138,525.00 |
| Mar 31, 2024 | -402,589.00 |
| Mar 31, 2024 | -402,589.00 |
| Dec 31, 2023 | 162,734.00 |
| Dec 31, 2023 | 162,734.00 |
| Sep 30, 2023 | 162,629.00 |
| Sep 30, 2023 | 162,629.00 |